Prax­is stock tanks af­ter mid-stage move­ment dis­or­der tri­al miss

Prax­is Pre­ci­sion Med­i­cines has missed its goal in a Phase IIb tri­al af­ter rolling out pos­i­tive Phase IIa re­sults last year.

The CNS-fo­cused biotech an­nounced Fri­day morn­ing that the mid-stage tri­al did not reach sta­tis­ti­cal sig­nif­i­cance in the study’s pri­ma­ry end­point. The Phase IIb tri­al, ex­am­in­ing drug can­di­date PRAX-944 in pa­tients with a con­di­tion called es­sen­tial tremor, showed the drug in­duced an av­er­age 3.01-point re­duc­tion from base­line in a dai­ly liv­ing ac­tiv­i­ty score, com­pared to a 1.44-point re­duc­tion from place­bo af­ter eight weeks.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER